Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin, quantity: 500 mg; clavulanic acid, quantity: 125 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate; dimeticone 5000; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; macrogol 6000; macrogol 4000 - augmentin tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology): urinary tract infections (uncomplicated and complicated); lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis; upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis; skin and skin structure infections. appropriate culture and susceptibility studies should be performed to identify the causative organisms(s) and its (their) susceptibility to augmentin tablets. however, when there is reason to believe an infection may involve any of the b-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and b-lactamase producing organisms susceptible to augmentin tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

Malta - İngilizce - Medicines Authority

norgine limited - macrogol 3350; sodium chloride; sodium hydrogen carbonate; potassium chloride - powder for oral solution - macrogol 3350 6.563 g; sodium chloride 175.4 mg; sodium hydrogen carbonate 89.3 mg; potassium chloride 25.1 mg - drugs for constipation

Malta - İngilizce - Medicines Authority

norgine bv antonio vivaldistraat 150, 1083 hp amsterdam, netherlands - macrogol, sodium chloride, sodium hydrogen, carbonate, potassium chloride - powder for oral solution - macrogol 3350 6.563 gram(s) ; sodium chloride 0.1754 gram(s) ; sodium hydrogen carbonate 0.0893 gram(s) ; potassium chloride 0.0251 gram(s) - drugs for constipation

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - pancreatic extract, quantity: 420 mg (equivalent: lipase, qty 35000 ph eur unit; equivalent: amylase, qty 25200 ph eur unit; equivalent: protease, qty 1400 ph eur unit) - capsule - excipient ingredients: macrogol 4000; hypromellose phthalate; cetyl alcohol; triethyl citrate; dimeticone 1000; gelatin; iron oxide red; iron oxide yellow; iron oxide black; titanium dioxide; sodium lauryl sulfate - creon is indicated as pancreatic enzyme replacement in paediatric and adult patients with pancreatic exocrine insufficiency (pei). pancreatic exocrine insufficiency is often associated with, but not limited to: ? cystic fibrosis ? chronic pancreatitis ? pancreatic surgery ? gastrointestinal bypass surgery (e.g. bilroth ii gastroenterostomy) ? ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm)

Malta - İngilizce - Medicines Authority

rowex ltd newtown bantry, co. cork, , ireland - macrogol, sodium chloride, sodium hydrogen, carbonate, potassium chloride - powder for oral solution - macrogol 3350 13.125 g sodium chloride 0.3507 g sodium hydrogen carbonate 0.1785 g potassium chloride 0.0466 g - drugs for constipation

Malta - İngilizce - Medicines Authority

stirling anglian pharmaceuticals ireland limited 3 burlington road, dublin 4, d04rd68, , ireland - macrogol, sodium chloride, sodium hydrogen, carbonate, potassium chloride - powder for oral solution - macrogol 3350 6.563 g sodium chloride 0.1754 g sodium hydrogen carbonate 0.0893 g potassium chloride 0.0233 g - drugs for constipation

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - deferasirox, quantity: 360 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; colloidal anhydrous silica; poloxamer; hypromellose; titanium dioxide; macrogol 4000; purified talc; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. deferasirox sandoz is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. deferasirox sandoz is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - deferasirox, quantity: 180 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; colloidal anhydrous silica; poloxamer; hypromellose; titanium dioxide; macrogol 4000; purified talc; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. deferasirox sandoz is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. deferasirox sandoz is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - deferasirox, quantity: 90 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; colloidal anhydrous silica; poloxamer; hypromellose; titanium dioxide; macrogol 4000; purified talc; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. deferasirox sandoz is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. deferasirox sandoz is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 1560 mg - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - invega hafyera, a 6-month injection, is indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months or the 3-month paliperidone palmitate injectable product following at least one 3-month injection cycle.